Patents by Inventor Conor Burke

Conor Burke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR RETARDATION
    Publication number: 20250241892
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from psychomotor retardation.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 31, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • TREATMENT OF MENTAL DISORDERS
    Publication number: 20250241894
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 31, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • TREATMENT OF COGNITIVE DYSFUNCTION
    Publication number: 20250241893
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from cognitive dysfunction.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 31, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Conor BURKE, Theis TERWEY, Naoise GAFFNEY
  • 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE
    Publication number: 20250241895
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from sleep disturbance.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 31, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • TREATMENT OF ANXIETY
    Publication number: 20250241891
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from anxiety.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 31, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF SOCIAL/EMOTIONAL WITHDRAWAL OR DETACHMENT
    Publication number: 20250235427
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from social/emotional withdrawal or detachment, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt a thereof is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 24, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-MEO-DMT FOR USE IN THE TREATMENT OF POSTPARTUM DEPRESSION
    Publication number: 20250221963
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD).
    Type: Application
    Filed: March 27, 2023
    Publication date: July 10, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-MEO-DMT FOR USE IN THE TREATMENT OF NEGATIVE THINKING
    Publication number: 20250213530
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from negative thinking, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 3, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF BIPOLAR DISORDER
    Publication number: 20250213532
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is diagnosed with bipolar disorder.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 3, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-MEO-DMT FOR USE IN THE TREATMENT OF SLEEP DISTURBANCE
    Publication number: 20250213533
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from sleep disturbance, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 3, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-METHOXY-N.N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF PSYCHOMOTOR RETARDATION
    Publication number: 20250213529
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from psychomotor retardation, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intra-venous, intramuscular or subcutaneous route.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 3, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF COGNITIVE DYSFUNCTION
    Publication number: 20250213534
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from cognitive dysfunction, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 3, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF ANXIETY
    Publication number: 20250213528
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from anxiety, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 3, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-MEO-DTM FOR THE TREATMENT OF BIPOLAR DISORDER
    Publication number: 20250213531
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is diagnosed with bipolar disorder, wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: March 27, 2023
    Publication date: July 3, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF SOCIAL/EMOTIONAL WITHDRAWAL OR DETACHMENT
    Publication number: 20250205199
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from social/emotional withdrawal or detachment.
    Type: Application
    Filed: March 27, 2023
    Publication date: June 26, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-MEO-DMT FOR USE IN THE TREATMENT OF NEGATIVE THINKING
    Publication number: 20250205256
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient who is suffering from negative thinking.
    Type: Application
    Filed: March 27, 2023
    Publication date: June 26, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • 5-METHOXY-N,N-DIMETHYLTRYPTAMINE FOR THE TREATMENT OF POSTPARTUM DEPRESSION
    Publication number: 20250205200
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD) wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: March 27, 2023
    Publication date: June 26, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • TREATMENT OF POSTNATAL DEPRESSION
    Publication number: 20250170099
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: March 27, 2023
    Publication date: May 29, 2025
    Applicant: GH RESEARCH IRELAND LIMITED
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • TREATMENT OF MENTAL DISORDERS
    Publication number: 20240115550
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in the treatment of a mental or nervous system disorder in a mother having a child of age 18 months or below, wherein the 5-MeO-DMT or a pharmaceutically acceptable salt thereof is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 11, 2024
    Applicant: GH Research Ireland Limited
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY
  • TREATMENT OF MENTAL DISORDERS
    Publication number: 20240115549
    Abstract: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) or a pharmaceutically acceptable salt thereof is used in treating a patient suffering from postpartum depression (PPD) wherein the 5-MeO-DMT is administered via the intravenous, intramuscular or subcutaneous route.
    Type: Application
    Filed: September 27, 2023
    Publication date: April 11, 2024
    Applicant: GH Research Ireland Limited
    Inventors: Theis TERWEY, Conor BURKE, Naoise GAFFNEY